CP-532623, a close structural analog of Torcetrapib, is a CETP inhibitor with highly lipophilic properties. It elevates high-density lipoprotein cholesterol.

CP-532623 alters the kinetics of lymph lipid transport and decreases lymph lipid transport in chylomicrons. CP-532623 is highly lymphatically transported (28% of the dose). However, it lymphatic transport is closely correlated with drug affinity for ex-vivo lymph lipoproteins or triglyceride emulsions. But, it has poorly related to solubility in mixtures of lipoprotein core and/or surface lipids [2].

CP-532623 (50 mg; p.o.; adult male greyhound dogs) treatment substantially transports into the lymphatic system (>25% dose) in fed and fasted dogs. Lymphatic triglyceride transport is significantly lower in fed dogs administered CP-532623. Food enhances oral bioavailability (from 44 to 58%, respectively) and the proportion of the absorbed dose transports via the lymph (from 61 to 86% and from 68 to 83%, respectively) [3].